First line of the email MUST contain NCT # and Site #.
CONTACT
Lead
Bristol-Myers Squibb
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening Visit
Evidence of UC extending beyond the rectum, as determined by baseline endoscopy
Has had an inadequate response, loss of response to, or is intolerant to at least 1 of the following treatments for UC: oral aminosalicylates, systemic corticosteroids, immunomodulators, biologic therapy
You may not be if
Diagnosis of Crohn's disease or indeterminate colitis
Has documentation of positive test for toxin producing Clostridium difficile, or polymerase chain reaction examination of the stool
Apheresis within 2 weeks of randomization
History of or currently active primary or secondary immunodeficiency, or participants with known genetic disorders as a cause for colitis
Clareo Health | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
